BRIEF-Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC Filing

Reuters

Aug 14

BRIEF-Protagenic <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Approves Restructuring Plan on August 8- SEC Filing

Aug 13 (Reuters) - Protagenic Therapeutics Inc PTIX.O:

PROTAGENIC THERAPEUTICS INC - ON AUGUST 8 APPROVES FOCUSED RESTRUCTURING PLAN - SEC FILING
PROTAGENIC THERAPEUTICS INC: RESTRUCTURING PLAN TO TRANSITION TO VIRTUAL OPERATING MODEL, CONCENTRATE CAPITAL ON HIGHEST-PRIORITY CLINICAL PROGRAM$(S)$
PROTAGENIC THERAPEUTICS INC: HAS TEMPORARILY SUSPENDED EXPENDITURES RELATED TO PRECLINICAL PROGRAMS
PROTAGENIC THERAPEUTICS INC: INITIATED PROCESS TO EVALUATE STRATEGIC ALTERNATIVES FOR THOSE PROGRAMS, INCLUDING PARTNERSHIPS AND/OR OUT-LICENSING
PROTAGENIC THERAPEUTICS INC: REDUCING OPERATING EXPENSES, OVERHEAD, AND HEADCOUNT PRIMARILY ASSOCIATED WITH PRECLINICAL ACTIVITIES
PROTAGENIC THERAPEUTICS : WHEN FULLY IMPLEMENTED, RESTRUCTURING PLAN IS EXPECTED TO REDUCE ANNUALIZED OPERATING EXPENSES BY ABOUT $8 MILLION
PROTAGENIC THERAPEUTICS : TERMINATED EMPLOYMENT OF BARRETT EVANS AS CEO AND PRESIDENT AND COLIN STOTT AS CHIEF OPERATING OFFICER
PROTAGENIC THERAPEUTICS INC: APPROVED A CHANGE IN CO'S FISCAL YEAR-END FROM DECEMBER 31 TO MARCH 31, EFFECTIVE IMMEDIATELY
PROTAGENIC THERAPEUTICS:ALL PRECLINICAL PROGRAMS ORIGINATED WITH FORMER PHYTANIX BIO (PHYX-001,PHYX-002,PHYX-003,PHYX-004, PHYX-005) HAVE BEEN PAUSED

Source text: [ID:n0001641172-25-023588]

Further company coverage: PTIX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2559898402"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559898402\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559898402?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-14 05:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559898402","market":"nz","top_or_hot":-1,"title":"BRIEF-Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC Filing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Protagenic <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Approves Restructuring Plan on August 8- SEC Filing</title></head><body><p><span>Aug 13 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/PTIX\">Protagenic Therapeutics Inc</a> <span>PTIX.O</span>:</p><ul><li><p>PROTAGENIC THERAPEUTICS INC - ON AUGUST 8 APPROVES FOCUSED RESTRUCTURING PLAN - SEC FILING</p></li><li><p>PROTAGENIC THERAPEUTICS INC: RESTRUCTURING PLAN TO TRANSITION TO VIRTUAL OPERATING MODEL, CONCENTRATE CAPITAL ON  HIGHEST-PRIORITY CLINICAL PROGRAM<a href=\"https://laohu8.com/S/S\">$(S)$</a></p></li><li><p>PROTAGENIC THERAPEUTICS INC: HAS TEMPORARILY SUSPENDED EXPENDITURES RELATED TO PRECLINICAL PROGRAMS</p></li><li><p>PROTAGENIC THERAPEUTICS INC: INITIATED PROCESS TO EVALUATE STRATEGIC ALTERNATIVES FOR THOSE PROGRAMS, INCLUDING PARTNERSHIPS AND/OR OUT-LICENSING</p></li><li><p>PROTAGENIC THERAPEUTICS INC: REDUCING OPERATING EXPENSES, OVERHEAD, AND HEADCOUNT PRIMARILY ASSOCIATED WITH PRECLINICAL ACTIVITIES</p></li><li><p>PROTAGENIC THERAPEUTICS : WHEN FULLY IMPLEMENTED, RESTRUCTURING PLAN IS EXPECTED TO REDUCE ANNUALIZED OPERATING EXPENSES BY ABOUT $8 MILLION</p></li><li><p>PROTAGENIC THERAPEUTICS : TERMINATED EMPLOYMENT OF BARRETT EVANS AS CEO AND PRESIDENT AND COLIN STOTT AS CHIEF OPERATING OFFICER</p></li><li><p>PROTAGENIC THERAPEUTICS INC: APPROVED A CHANGE IN CO'S FISCAL YEAR-END FROM DECEMBER 31 TO MARCH 31, EFFECTIVE IMMEDIATELY</p></li><li><p>PROTAGENIC THERAPEUTICS:ALL PRECLINICAL PROGRAMS ORIGINATED WITH FORMER PHYTANIX BIO (PHYX-001,PHYX-002,PHYX-003,PHYX-004, PHYX-005) HAVE BEEN PAUSED</p></li></ul><p>Source text: [ID:n0001641172-25-023588]</p><p>Further company coverage: <span>PTIX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-14 05:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Protagenic <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Approves Restructuring Plan on August 8- SEC Filing</title></head><body><p><span>Aug 13 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/PTIX\">Protagenic Therapeutics Inc</a> <span>PTIX.O</span>:</p><ul><li><p>PROTAGENIC THERAPEUTICS INC - ON AUGUST 8 APPROVES FOCUSED RESTRUCTURING PLAN - SEC FILING</p></li><li><p>PROTAGENIC THERAPEUTICS INC: RESTRUCTURING PLAN TO TRANSITION TO VIRTUAL OPERATING MODEL, CONCENTRATE CAPITAL ON  HIGHEST-PRIORITY CLINICAL PROGRAM<a href=\"https://laohu8.com/S/S\">$(S)$</a></p></li><li><p>PROTAGENIC THERAPEUTICS INC: HAS TEMPORARILY SUSPENDED EXPENDITURES RELATED TO PRECLINICAL PROGRAMS</p></li><li><p>PROTAGENIC THERAPEUTICS INC: INITIATED PROCESS TO EVALUATE STRATEGIC ALTERNATIVES FOR THOSE PROGRAMS, INCLUDING PARTNERSHIPS AND/OR OUT-LICENSING</p></li><li><p>PROTAGENIC THERAPEUTICS INC: REDUCING OPERATING EXPENSES, OVERHEAD, AND HEADCOUNT PRIMARILY ASSOCIATED WITH PRECLINICAL ACTIVITIES</p></li><li><p>PROTAGENIC THERAPEUTICS : WHEN FULLY IMPLEMENTED, RESTRUCTURING PLAN IS EXPECTED TO REDUCE ANNUALIZED OPERATING EXPENSES BY ABOUT $8 MILLION</p></li><li><p>PROTAGENIC THERAPEUTICS : TERMINATED EMPLOYMENT OF BARRETT EVANS AS CEO AND PRESIDENT AND COLIN STOTT AS CHIEF OPERATING OFFICER</p></li><li><p>PROTAGENIC THERAPEUTICS INC: APPROVED A CHANGE IN CO'S FISCAL YEAR-END FROM DECEMBER 31 TO MARCH 31, EFFECTIVE IMMEDIATELY</p></li><li><p>PROTAGENIC THERAPEUTICS:ALL PRECLINICAL PROGRAMS ORIGINATED WITH FORMER PHYTANIX BIO (PHYX-001,PHYX-002,PHYX-003,PHYX-004, PHYX-005) HAVE BEEN PAUSED</p></li></ul><p>Source text: [ID:n0001641172-25-023588]</p><p>Further company coverage: <span>PTIX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nFWN3U51UE:1","article_id":"2559898402","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559898402","pubTimestamp":1755122262,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC FilingAug 13 (Reuters) - Protagenic Therapeutics Inc PTIX.O:PROTAGENIC THERAPEUTICS INC - ON AUGUST 8 APPROVES FOCUSED RESTRU","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PTIX":"Protagenic Therapeutics Inc"},"translate_title":"简介-Protagenic Therapeutics于8月8日批准重组计划-SEC备案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTIX":0.9},"content_text":"BRIEF-Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC FilingAug 13 (Reuters) - Protagenic Therapeutics Inc PTIX.O:PROTAGENIC THERAPEUTICS INC - ON AUGUST 8 APPROVES FOCUSED RESTRUCTURING PLAN - SEC FILINGPROTAGENIC THERAPEUTICS INC: RESTRUCTURING PLAN TO TRANSITION TO VIRTUAL OPERATING MODEL, CONCENTRATE CAPITAL ON  HIGHEST-PRIORITY CLINICAL PROGRAM$(S)$PROTAGENIC THERAPEUTICS INC: HAS TEMPORARILY SUSPENDED EXPENDITURES RELATED TO PRECLINICAL PROGRAMSPROTAGENIC THERAPEUTICS INC: INITIATED PROCESS TO EVALUATE STRATEGIC ALTERNATIVES FOR THOSE PROGRAMS, INCLUDING PARTNERSHIPS AND/OR OUT-LICENSINGPROTAGENIC THERAPEUTICS INC: REDUCING OPERATING EXPENSES, OVERHEAD, AND HEADCOUNT PRIMARILY ASSOCIATED WITH PRECLINICAL ACTIVITIESPROTAGENIC THERAPEUTICS : WHEN FULLY IMPLEMENTED, RESTRUCTURING PLAN IS EXPECTED TO REDUCE ANNUALIZED OPERATING EXPENSES BY ABOUT $8 MILLIONPROTAGENIC THERAPEUTICS : TERMINATED EMPLOYMENT OF BARRETT EVANS AS CEO AND PRESIDENT AND COLIN STOTT AS CHIEF OPERATING OFFICERPROTAGENIC THERAPEUTICS INC: APPROVED A CHANGE IN CO'S FISCAL YEAR-END FROM DECEMBER 31 TO MARCH 31, EFFECTIVE IMMEDIATELYPROTAGENIC THERAPEUTICS:ALL PRECLINICAL PROGRAMS ORIGINATED WITH FORMER PHYTANIX BIO (PHYX-001,PHYX-002,PHYX-003,PHYX-004, PHYX-005) HAVE BEEN PAUSEDSource text: [ID:n0001641172-25-023588]Further company coverage: PTIX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}